Get the Stockscreener App
1.47
3.52%
0.05
After Hours:
1.42
-0.05
-3.40%
Marker Therapeutics Inc stock is traded at $1.47, with a volume of 251.82K.
It is up +3.52% in the last 24 hours and up +55.79% over the past month.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.
See More
Previous Close:
$1.42
Open:
$1.45
24h Volume:
251.82K
Relative Volume:
0.94
Market Cap:
$24.51M
Revenue:
-
Net Income/Loss:
$-9.70M
P/E Ratio:
-1.3364
EPS:
-1.1
Net Cash Flow:
$-8.57M
1W Performance:
+11.36%
1M Performance:
+55.79%
6M Performance:
-13.02%
1Y Performance:
-68.86%
1-Day Range:
$1.42
$1.48
1-Week Range:
$1.31
$1.49
52-Week Range:
$0.8099
$5.95
Marker Therapeutics Inc Stock (MRKR) Company Profile
Name
Marker Therapeutics Inc
Sector
Industry
Phone
(713) 400-6400
Address
2450 HOLCOMBE BLVD, HOUSTON, TX
Compare MRKR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRKR
Marker Therapeutics Inc
|
1.47 | 23.68M | 0 | -9.70M | -8.57M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Marker Therapeutics Inc Stock (MRKR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-25 | Initiated | Canaccord Genuity | Buy |
| Mar-25-21 | Initiated | Piper Sandler | Overweight |
| Mar-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-12-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| Mar-01-19 | Initiated | Janney | Buy |
| Dec-03-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
View All
Marker Therapeutics Inc Stock (MRKR) Latest News
Panic Selling: Is Marker Therapeutics Inc stock supported by strong cash flows2025 Pullback Review & Reliable Momentum Entry Alerts - moha.gov.vn
Published on: 2025-12-13 20:42:44 - moha.gov.vn
What drives Marker Therapeutics Inc GX1 stock priceDividend Stability Analysis & Consistent Triple Returns - earlytimes.in
FY2025 Earnings Forecast for MRKR Issued By HC Wainwright - Defense World
Marker Therapeutics (NASDAQ:MRKR) Coverage Initiated at HC Wainwright - Defense World
H.C. Wainwright reiterates Buy rating on Marker Therapeutics stock By Investing.com - Investing.com Canada
HC Wainwright & Co. Initiates Coverage of Marker Therapeutics (MRKR) with Buy Recommendation - Nasdaq
MRKR: HC Wainwright & Co. Initiates Coverage with a 'Buy' Rating - GuruFocus
Is Marker Therapeutics Inc GX1 a good long term investmentExit Strategy Tips & Never Miss the Next Wealth Opportunity - earlytimes.in
Check Out Lam Research Corp (LRCX)’s Trade Data Rather Than the Analysts’ Views - setenews.com
Why Marker Therapeutics Inc. stock remains on watchlistsWeekly Trend Report & AI Forecasted Stock Moves - Newser
How analysts revise price targets for Marker Therapeutics Inc. (GX1) stockJuly 2025 Patterns & Precise Swing Trade Entry Alerts - Newser
Acute Myeloid Leukemia Clinical Trial Pipeline Appears Robust With 100+ Key Pharma Companies Actively Working in the Domain | DelveInsight - Business Upturn
Is Marker Therapeutics Inc. stock supported by innovation pipelineMarket Performance Recap & Advanced Technical Signal Analysis - Newser
Is Marker Therapeutics Inc. (GX1) stock good for long term investingJuly 2025 PostEarnings & Safe Entry Trade Reports - Newser
Why ETFs are accumulating Marker Therapeutics Inc. (GX1) stockProduct Launch & Safe Entry Trade Signal Reports - Newser
Recovery Setup Building in AVI Polymers Limited Experts SayPrice-to-Earnings Ratio Insights & Capital Planning and Optimization - earlytimes.in
Marker Therapeutics (MRKR) Stock Analysis Report | Financials & Insights - Benzinga
Marker Therapeutics (NASDAQ:MRKR) Downgraded by Wall Street Zen to Sell - Defense World
What insider trading reveals about Marker Therapeutics Inc. stockWeekly Trading Summary & High Accuracy Swing Entry Alerts - moha.gov.vn
Marker Therapeutics Inc (MRKR) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Marker Therapeutics Inc. (MRKR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Marker Therapeutics Experiences Revision in Its Stock Evaluation Amid Financial Challenges - Markets Mojo
Head-To-Head Contrast: Central Puerto (NYSE:CEPU) vs. Enovix (NASDAQ:ENVX) - Defense World
Marker Therapeutics (NASDAQ:MRKR) Upgraded at Zacks Research - Defense World
How Marker Therapeutics Inc. stock performs during Fed tightening cycles2025 Support & Resistance & Consistent Profit Alerts - newser.com
Taking the lead: Marker Therapeutics Inc (MRKR) - setenews.com
What Fibonacci levels say about Marker Therapeutics Inc. rebound2025 Technical Overview & Real-Time Market Sentiment Alerts - newser.com
Is Marker Therapeutics Inc. stock safe for conservative investorsJuly 2025 Earnings & Capital Efficiency Focused Ideas - newser.com
Can Marker Therapeutics Inc. (GX1) stock hit consensus price targetsIndex Update & Risk Controlled Swing Trade Alerts - newser.com
Is Marker Therapeutics Inc. reversing from oversold territorySell Signal & Community Consensus Trade Alerts - newser.com
[Form 4] Marker Therapeutics, Inc. Insider Trading Activity - Stock Titan
How to interpret RSI for Marker Therapeutics Inc. stock2025 Volatility Report & Weekly Consistent Profit Watchlists - newser.com
Can volume confirm reversal in Marker Therapeutics Inc.Market Performance Summary & Precise Swing Trade Alerts - newser.com
What makes Marker Therapeutics Inc. (GX1) stock appealing to growth investorsChart Signals & Safe Capital Investment Plans - newser.com
Is Marker Therapeutics Inc. stock a buy on dips2025 Earnings Surprises & Safe Entry Point Alerts - newser.com
Marker Therapeutics Reports Q3 2025 Financial Results - TipRanks
Marker Therapeutics Inc Stock (MRKR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Marker Therapeutics Inc Stock (MRKR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| New Enterprise Associates 16, | 10% Owner |
Dec 23 '24 |
Buy |
3.20 |
554,250 |
1,773,600 |
1,625,678 |
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):